This month, I’m focusing on how to optimize anti-TNF treatment decisions.
The first topic I chose to look at is the use of proactive therapeutic drug monitoring (TDM). Based on limited data, the practice is thought to improve outcomes, but the trial I’ve highlighted—which included patients with IBD and other illnesses treated with infliximab.